Page 266 - Glucose Monitoring Devices

References 273

[40] Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ,
Welsh JB, Lee SW, Kaufman FR. ASPIRE In-Home Study Group. Threshold-based
insulin-pump interruption for reduction of hypoglycemia. New England Journal of
Medicine July 18, 2013;369(3):224e32.
[41] Sherr JL, Palau Collazo M, Cengiz E, et al. Safety of nighttime 2-hour suspension of
Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose. Dia-
betes Care 2014;37(3):773e9.
[42] Elbarbary NS. Effectiveness of the low-glucose suspend feature of insulin pump during
fasting during Ramadan in type 1 diabetes mellitus. Diabetes/Metabolism Research and
Reviews September 2016;32(6):623e33.
[43] Ahmed MH, Husain NE, Elmadhoun WM, Noor SK, Khalil AA, Almobarak AO. Dia-
betes and Ramadan: a concise and practical update. Journal of Family Medicine and Pri-
mary Care 2017 ;6(1):11e8.
[44] Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L,
Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ,
Califf RM. Real-world evidence - what is it and what can it tell us? New England Jour-
nal of Medicine December 8, 2016;375(23):2293e7.
[45] Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR. Usage and effective-
ness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump.
Journal of Diabetes Science and Technology September 1, 2011;5(5):1137e41.
[46] Go ´mez AM, Marı ´n Carrillo LF, Mun ˜oz Velandia OM, Rondo ´n Sepu ´lveda MA, Are ´valo
Correa CM, Mora Garzo ´n E, Cuervo Diaz MC, Henao Carrillo DC. Long-term efficacy
and safety of sensor augmented insulin pump therapy with low-glucose suspend feature
in patients with type 1 diabetes. Diabetes Technology and Therapeutics February 2017;
19(2):109e14.
[47] Agrawal P, Zhong A, Welsh JB, Shah R, Kaufman FR. Retrospective analysis of the
real-world use of the threshold suspend feature of sensor-augmented insulin pumps.
Diabetes Technology and Therapeutics May 2015;17(5):316e9.
[48] Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-
effectiveness analysis in health and medicine. Panel on cost-effectiveness in health
and medicine. Journal of the American Academy of Dermatology October 9, 1996;
276(14):1172e7.
[49] Ly TT, Brnabic AJ, Eggleston A, et al. A cost-effectiveness analysis of sensor-
augmented insulin pump therapy and automated insulin suspension versus standard
pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value in Health
2014;17:561e9.
[50] Sussman M, Sierra J, Garg S, Bode B, Friedman M, Gill M, Kaufman F, Vigersky R,
Menzin J. Economic impact of hypoglycemia among insulin-treated patients with
diabetes. Journal of Medical Economics 2016;19(11):1099e106.
´
[51] Conget I, Martı ´n-Vaquero P, Roze S, Elı ´as I, Pineda C, Alvarez M, Delbaere A,
Ampudia-Blasco FJ. Cost-effectiveness analysis of sensor-augmented pump therapy
with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hy-
poglycemia in Spain. Endocrinology, Diabetes and Nutrition 2018 Aug - Sep;65(7):
380e6.